Latest Blog Posts Tagged "Repositioning"
October 08, 2018
A recent MJFF-supported study found that nicotine patches do not slow progression in people with early, untreated Parkinson's disease.
July 12, 2016
Today MJFF, the Van Andel Research Institute and the Cure Parkinson's Trust announced plans to collaborate to assess the clinical use and development of cancer drug nilotinib.
July 27, 2015
Tanya Simuni, MD, spoke to us about results from a trial of diabetes drug pioglitazone for PD treatment and what her team's findings mean for this vein of Parkinson's research.
October 10, 2014
A drug developed for the genetic disorder Gaucher disease has shown promising results for treating Parkinson's disease in pre-clinical models.
June 27, 2014
The Alzheimer's Drug Discovery Foundation and MJFF published an article outlining how partner organizations can advance repurposing of FDA-approved drugs for the treatment of brain diseases.
October 18, 2013
While repurposing is no more guaranteed to yield new treatments than any other line of inquiry, Palfreman lays out the case for its potential in Parkinson's disease.
September 18, 2013
Every research project we fund is a step closer to new and better therapies for people with Parkinson's disease. Here we've highlighted our most exciting, newly funded grants.
July 30, 2013
Could that medication you're taking to lower your cholesterol also prevent PD? Maybe, says a new population-based study from researchers in Taiwan.
July 03, 2013
Repositioning is the process of testing a drug that is already FDA-approved or that has been proven safe for a certain indication, to determine whether it might work in another disease, such as PD.
October 01, 2012
A recent online commentary in The New York Times makes the case that Alzheimer's disease (AD) may in fact be a third type of diabetes, citing new and "increasingly persuasive" studies.